Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Efficacy and safety of low-dose aspirin in polycythemia vera.

Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators.

N Engl J Med. 2004 Jan 8;350(2):114-24.

2.

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE.

N Engl J Med. 2005 Mar 31;352(13):1293-304. Epub 2005 Mar 7.

3.

Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.

Steinhubl SR, Bhatt DL, Brennan DM, Montalescot G, Hankey GJ, Eikelboom JW, Berger PB, Topol EJ; CHARISMA Investigators.

Ann Intern Med. 2009 Mar 17;150(6):379-86.

PMID:
19293071
4.

European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial.

Landolfi R, Marchioli R.

Semin Thromb Hemost. 1997;23(5):473-8.

PMID:
9387206
5.
6.

A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP).

Finazzi G; low-dose aspirin in polycythemia (ECLAP).

Pathol Biol (Paris). 2004 Jun;52(5):285-8.

PMID:
15217715
7.

Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators.

N Engl J Med. 2007 Nov 15;357(20):2001-15. Epub 2007 Nov 4.

8.

Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.

Teramoto T, Shimada K, Uchiyama S, Sugawara M, Goto Y, Yamada N, Oikawa S, Ando K, Ishizuka N, Yamazaki T, Yokoyama K, Murata M, Ikeda Y.

Am Heart J. 2010 Mar;159(3):361-369.e4. doi: 10.1016/j.ahj.2009.11.030.

PMID:
20211296
9.

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.

N Engl J Med. 2001 Aug 16;345(7):494-502. Erratum in: N Engl J Med 2001 Nov 15;345(20):1506. N Engl J Med 2001 Dec 6;345(23):1716.

10.

Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.

Squizzato A, Romualdi E, Middeldorp S.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006503. doi: 10.1002/14651858.CD006503.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;4:CD006503.

PMID:
18425953
11.

Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.

Berger JS, Brown DL, Becker RC.

Am J Med. 2008 Jan;121(1):43-9. doi: 10.1016/j.amjmed.2007.10.002. Review.

PMID:
18187072
12.

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.

De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T; GIMEMA CMD-Working Party.

Haematologica. 2008 Mar;93(3):372-80. doi: 10.3324/haematol.12053. Epub 2008 Feb 11.

13.

A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement.

Turpie AG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J.

N Engl J Med. 1993 Aug 19;329(8):524-9.

14.

Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S.

N Engl J Med. 2009 May 14;360(20):2066-78. doi: 10.1056/NEJMoa0901301. Epub 2009 Mar 31.

15.

Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.

Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators.

N Engl J Med. 2005 Mar 31;352(13):1305-16.

16.

Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.

Squizzato A, Romualdi E, Passamonti F, Middeldorp S.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD006503. doi: 10.1002/14651858.CD006503.pub3. Review.

PMID:
23633335
17.

Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.

Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, Sugawara M, Ando K, Murata M, Yokoyama K, Ishizuka N.

JAMA. 2014 Dec 17;312(23):2510-20. doi: 10.1001/jama.2014.15690.

PMID:
25401325
18.

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.

Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, Brennan DM, Hacke W, Montalescot G, Steinhubl SR, Topol EJ; CHARISMA Investigators.

Circulation. 2010 Jun 15;121(23):2575-83. doi: 10.1161/CIRCULATIONAHA.109.895342. Epub 2010 Jun 1.

19.

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.

Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E; CLARITY-TIMI 28 Investigators.

N Engl J Med. 2005 Mar 24;352(12):1179-89. Epub 2005 Mar 9.

20.

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators.

N Engl J Med. 2006 Apr 20;354(16):1706-17. Epub 2006 Mar 12.

Supplemental Content

Support Center